IMMUNIC, INC. 8-K

What Happened
Immunic, Inc. (IMUX) announced via Form 8-K filed March 31, 2026, that Jon Congleton was appointed to its Board of Directors effective March 27, 2026. Mr. Congleton will serve as a Class II director through the Company’s 2028 annual meeting and will act as Chair of the Board’s Compensation Committee. The Board size was increased from eight to nine directors in connection with his appointment.

Key Details

• Appointment effective date: March 27, 2026; 8-K filed: March 31, 2026.
• Term: Class II director through the 2028 annual meeting of stockholders.
• Compensation: inaugural option grant to purchase up to 500,000 shares, vesting monthly over three years; exercise price = closing Nasdaq price on March 27, 2026. Grant is subject to shareholder approval to increase shares reserved under the 2019 Omnibus Equity Incentive Plan.
• Other pay: Mr. Congleton will receive cash director compensation per the Company’s non‑employee director policy and entered the Company’s standard indemnification agreement.
• Background: age 62; current President & CEO of Mineralys Therapeutics (since Nov 2020); prior CEO roles at Impel NeuroPharma and Nivalis; 18+ years at Teva in senior commercial and global marketing roles; B.S. in marketing from Kansas State University.

Why It Matters
A new board member and Compensation Committee chair can influence executive pay policies and governance practices. The stock option award aligns Mr. Congleton’s pay with shareholder outcomes but requires shareholder approval to increase plan reserves before issuance. Investors should note the governance change (board expanded to nine members) and the potential for changes in compensation oversight, while monitoring any related filings (proxy proposals, future 8‑Ks) for shareholder votes or additional details.